76_CD GlaxoSmithKline_NNP Consolidated_NNP statement_NN of_IN profit_NN and_CC loss_NN for_IN the_DT year_NN ended_VBD 31st_CD December_NNP 2002_CD 2002_CD Merger_NNP ,_, restructuring_VBG Business_NN and_CC disposal_NN performance_NN of_IN subsidiaries_NNS Statutory_NNP Notes_NNP m_FW m_FW m_FW Turnover_NN 6_CD 21,212_CD 21,212_CD Cost_NN of_IN sales_NNS 4,243_CD 366_CD 4,609_CD Gross_NNP profit_NN 16,969_CD 366_CD 16,603_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ expenditure_NN 7,543_CD 498_CD 8,041_CD Research_NNP and_CC development_NN expenditure_NN 2,732_CD 168_CD 2,900_CD Trading_NN profit_NN 6,694_CD 1,032_CD 5,662_CD Other_JJ operating_NN income_NN expense_NN 8_CD 111_CD 111_CD Operating_NN profit_NN 7,9_CD 6,583_CD 1,032_CD 5,551_CD Share_NN of_IN profits_NNS losses_NNS of_IN joint_JJ ventures_NNS and_CC associated_VBN undertakings_NNS 10_CD 75_CD 75_CD profit_NN on_IN disposal_NN of_IN interest_NN in_IN associate_JJ 31_CD Product_NN divestments_NNS 7_CD 11_CD 11_CD Merger_NN transaction_NN costs_NNS 7_CD profit_NN loss_NN on_IN disposal_NN of_IN businesses_NNS 7_CD 10_CD 10_CD profit_NN before_IN interest_NN 6,658_CD 1,011_CD 5,647_CD Net_JJ interest_NN payable_JJ 11 141 141_CD profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 6,517_CD 1,011_CD 5,506_CD Taxation_NNP 7,12_CD 1,760_CD 299_CD 1,461_CD profit_NN on_IN ordinary_JJ activities_NNS after_IN taxation_NN 4,757_CD 712_CD 4,045_CD Minority_NNP interests_NNS 110_CD 110_CD Preference_NN share_NN dividends_NNS 20_CD 20_CD Earnings_NNS profit_NN attributable_JJ to_TO shareholders_NNS 13_CD 4,627_CD 712_CD 3,915_CD Basic_JJ earnings_NNS per_IN share_NN 13_CD 66.2_CD p_NN Adjusted_VBN earnings_NNS per_IN share_NN 13_CD 78.3_CD p_NN Diluted_VBN earnings_NNS per_IN share_NN 13_CD 66.0_CD p_NN profit_NN attributable_JJ to_TO shareholders_NNS 3,915_CD Dividends_NNPS 14_CD 2,346_CD Retained_VBN profit_NN 1,569_CD All_DT items_NNS dealt_VBD with_IN in_IN arriving_VBG at_IN business_NN performance_NN operating_NN profit_NN relate_VBP to_TO continuing_VBG activities_NNS ._.
There_EX is_VBZ no_DT difference_NN between_IN the_DT profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN and_CC the_DT retained_VBN profit_NN stated_VBN above_IN and_CC their_PRP$ historical_JJ cost_NN equivalents_NNS ._.
During_IN 2002_CD ,_, FRS_NNP 19_CD Deferred_NNP Tax_NNP has_VBZ been_VBN implemented_VBN by_IN the_DT Group_NNP ._.
This_DT FRS_NNP requires_VBZ deferred_JJ tax_NN to_TO be_VB accounted_VBN for_IN on_IN a_DT full_JJ provision_NN basis_NN ,_, rather_RB than_IN a_DT partial_JJ provision_NN basis_NN as_IN in_IN 2001_CD and_CC earlier_JJR years_NNS ._.
This_DT change_NN has_VBZ been_VBN accounted_VBN for_IN as_IN a_DT prior_JJ year_NN adjustment_NN and_CC comparative_JJ information_NN has_VBZ been_VBN restated_VBN as_RB necessary_JJ ._.
